SOLTIVE™ Laser Enucleation for Treatment of Benign Prostatic Hyperplasia
SOLTIVE™ Laser Enucleation for Treatment of Benign Prostatic Hyperplasia
To compare intraoperative as well as postoperative outcomes of SOLTIVE Thulium Fiber Laser
 Enucleation of the Prostate (ThuFLEP) vs Holmium Laser Enucleation of the Prostate.

 Our hypothesis is that utilizing the SOLTIVE Thulium laser enucleation of the prostate will
 result in a more efficient procedure, comparable results to that of Holmium laser enucleation
 of the prostate and subjective improvement of prior device limitations
Thulium laser is continuous wave laser which offers numerous potential benefits compared to
 alternative lasers and surgical procedures used for BPH. The SOLTIVE Laser system is a
 compact system which is significantly smaller than Holmium laser systems. The laser fiber is
 also smaller in diameter allowing for improved maneuverability with decreased fiber
 degradation and endoscope damage. The continuous wave pattern produces fast, hemostatic cuts
 during the removal and furthermore the associated hemostasis improves the visual field.
 Additionally, based on the 1940nm wavelength is absorbed nearly five times more in water. For
 all the stated reasons, the SOLTIVE Thulium Laser should improve the enucleation efficiency
 and warrants further investigation.
Inclusion Criteria:

 1. Patients must be 18 years of age or older

 2. Patients must be diagnosed with benign prostatic hyperplasia

 3. Patients must opt for surgical management of their BPH with laser enucleation

 Exclusion Criteria:

 1. Patients with a concomitant neurogenic bladder diagnosis (SCI, Parkinson, MS, cerebral
 palsy)

 2. Patients with prostate glands greater or equal to 200 grams

 3. Patients who are enrolled in other surgical or interventional trials at the time of
 this study are not eligible.